Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists
CA 2411914 C · Owner: Hadasit Medical Research Services & Development Of Hadassah University Hospital · Inventors: Pera, Martin Frederick
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
ES cells have a natural tendency to differentiate into cells resembling those of the extra-embryonic endodermal lineages in the early human embryo. Applicants have found that culturing ES cells in the presence of direct and/or indirect antagonists of the BMP-mediated default pathway of extra-embryonic endoderm differentiation will prevent ES cells from proceeding along this pathway.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 20, 2001 and granted August 21, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.